STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) has been assigned a consensus recommendation of “Sell” from the six analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and two have issued a hold recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is €72.91 ($86.80).

SAZ has been the topic of a number of analyst reports. Nord/LB set a €65.53 ($78.01) price target on shares of STADA Arzneimittel Aktiengesellschaft and gave the company a “sell” rating in a research report on Thursday, August 31st. Independent Research set a €76.00 ($90.48) price target on shares of STADA Arzneimittel Aktiengesellschaft and gave the company a “sell” rating in a research report on Tuesday, August 29th. Commerzbank set a €66.25 ($78.87) price target on shares of STADA Arzneimittel Aktiengesellschaft and gave the company a “sell” rating in a research report on Tuesday, August 22nd. Warburg Research set a €74.40 ($88.57) price target on shares of STADA Arzneimittel Aktiengesellschaft and gave the company a “sell” rating in a research report on Tuesday, September 5th. Finally, S&P Global set a €74.40 ($88.57) price target on shares of STADA Arzneimittel Aktiengesellschaft and gave the company a “sell” rating in a research report on Friday, November 10th.

Shares of STADA Arzneimittel Aktiengesellschaft (ETR SAZ) opened at €80.80 ($96.19) on Friday. STADA Arzneimittel Aktiengesellschaft has a 1 year low of €43.38 ($51.64) and a 1 year high of €83.91 ($99.89).

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/09/stada-arzneimittel-aktiengesellschaft-saz-given-consensus-rating-of-sell-by-brokerages.html.

STADA Arzneimittel Aktiengesellschaft Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel Aktiengesellschaft (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.